, a biopharmaceutical firm developing novel, proprietary antibodies for the treating cancer, inflammation and autoimmune illnesses today announced that Bayer Schering Pharma AG offers exercised its option beneath the option, collaboration and license contract entered into on January 12, 2009 to develop a fresh BiTE antibody for the treating solid tumors. Beneath the conditions of the agreement, Bayer Schering Pharma had a choice until January 5, 2010 to permit a particular BiTE antibody targeting an undisclosed focus on. The option workout triggers a formal collaboration between Micromet and Bayer Schering Pharma on the advancement of the BiTE antibody.‘I would have felt simply as horrified and just as unpleasant,’ Sarma said. ‘I would have felt as if my school was discriminating against me.’ To vent her frustration, Sarma considered Facebook, publishing an open up letter to her school, saying in-component: ‘You’re telling learners that it’s more important to lose pounds than to become healthful’ and ‘you discriminate predicated on weight by compiling a list of quote on quote fat students.